Caisse DE Depot ET Placement DU Quebec Has $4.21 Million Stock Holdings in Insulet Co. (NASDAQ:PODD)

Caisse DE Depot ET Placement DU Quebec trimmed its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 77.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,118 shares of the medical instruments supplier's stock after selling 54,095 shares during the quarter. Caisse DE Depot ET Placement DU Quebec's holdings in Insulet were worth $4,208,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Freestone Grove Partners LP acquired a new stake in shares of Insulet during the 4th quarter worth about $416,000. Northern Trust Corp boosted its holdings in shares of Insulet by 20.5% in the 4th quarter. Northern Trust Corp now owns 738,811 shares of the medical instruments supplier's stock worth $192,881,000 after acquiring an additional 125,710 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new stake in Insulet during the 4th quarter worth approximately $371,000. Virtus ETF Advisers LLC bought a new position in Insulet in the 4th quarter valued at $1,288,000. Finally, Integrated Wealth Concepts LLC boosted its stake in Insulet by 39.1% in the fourth quarter. Integrated Wealth Concepts LLC now owns 3,562 shares of the medical instruments supplier's stock worth $930,000 after purchasing an additional 1,001 shares in the last quarter.

Insulet Stock Down 2.8 %

Shares of NASDAQ:PODD traded down $7.31 during midday trading on Thursday, reaching $257.00. 1,282,622 shares of the company were exchanged, compared to its average volume of 717,147. The firm has a market cap of $18.08 billion, a PE ratio of 44.39, a P/E/G ratio of 3.62 and a beta of 1.26. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The stock has a fifty day simple moving average of $256.95 and a two-hundred day simple moving average of $262.85.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. During the same period last year, the firm posted $0.73 EPS. The business's revenue was up 28.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Insulet Co. will post 3.92 earnings per share for the current year.

Insider Activity at Insulet

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the transaction, the director now directly owns 3,231 shares of the company's stock, valued at approximately $888,525. This trade represents a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.47% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have commented on PODD. Wells Fargo & Company set a $322.00 price objective on shares of Insulet in a report on Monday, April 28th. Royal Bank of Canada began coverage on Insulet in a research note on Thursday, March 6th. They issued an "outperform" rating and a $340.00 target price for the company. Citigroup upped their price target on Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Piper Sandler boosted their price objective on Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Finally, Stifel Nicolaus raised their target price on shares of Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a research note on Friday, February 21st. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $299.81.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.